BioNTech Investor Day Presentation Deck
2 Variant-adapted vaccines | Omicron BA.1 sero response rate exceeds
non inferiority criterion for Omicron-containing vaccines (>55y participants)
Participants WITHOUT evidence of infection up to 1 month after the study vaccination
Assay
SARS-CoV-2
neutralization
assay -
Omicron
BA.1 - NT50
(titer)
Vaccine groups
BNT162b2 30 µg
BNT162b2 OMI 30 µg
BNT162b2 OMI 60 µg
1
Bivalent OMI 30 µg ¹
Bivalent OMI 60 µg²
N
149
163
166
169
162
n (%)
85 (57.0)
125 (76.7)
143 (86.1)
121 (71.6)
110 (67.9)
(95% CI)
1M post-dose
(48.7, 65.1)
(69.4, 82.9)
(79.9, 91.0)
(64.2, 78.3)
(60.1, 75.0)
%
(95% CI)
Seroresponse difference in %
Vaccine group - BNT162b2 30 μµg
Met non-inferiority
(Y/N)¹
19.6
(9.3, 29.7)
29.1
(19.4, 38.5)
14.6
(4.0, 24.9)
10.9
(0.1, 21.4)
Y
Y
Y
NUA
Y
Pandemic prep.
CAR
Non-inferiority criterion: the lower bound of 95% confidence interval for interval for the percentage difference is >-5
1 Multiple hypotheses are to be evaluated in sequential order for alpha control. Declaration of OMI 30 ug non inferiority pending outcome of additional hypotheses.
Note: Omicron BA.1 NT50 measured using validated 384-well assay.
Internal data.
Pfizer BIONTECH
69View entire presentation